H.R. 9635 aims to amend existing laws related to the Federal Food, Drug, and Cosmetic Act. The bill proposes special rules that would allow the continued review of human drug and device submissions even during periods when the government is not funded, known as a lapse of appropriations. This means that the approval process for new drugs and medical devices would not be halted due to budgetary issues.
Supporters of H.R. 9635 have praised the bill for its potential to ensure that critical medical advancements are not delayed due to funding issues. They argue that maintaining the review process for drugs and devices is essential for public health, especially during emergencies when timely access to new treatments can save lives.
Critics of H.R. 9635 have expressed concerns that allowing reviews to continue during funding lapses could undermine the regulatory process. They argue that it may lead to rushed approvals without adequate oversight, potentially compromising patient safety. Some media outlets have highlighted the risks of prioritizing speed over thorough evaluation in drug and device approval.
The bill H.R. 9635 aims to amend the Federal Food, Drug, and Cosmetic Act to ensure continued review of human drug and device submissions during appropriations lapses. The sponsor, Kevin Mullin, has significant financial backing from the health professionals sector, totaling $120 million. However, there is no direct industry overlap between the bill's subject matter and the sponsor's top donor industries, which include health professionals and retirees. This absence of overlap suggests that the financial interests of the donors do not directly influence the legislation being proposed. Therefore, while the financial contributions are substantial, they do not create a clear conflict of interest regarding the bill's intent or provisions.
These industries are both affected by this bill and among the sponsor's top donors.
| Industry | Match Type | Related Subject | Donations |
|---|---|---|---|
| Health Professionals (H01) | Sector | Health | $120,000,000 |
| Total from overlapping industries | $120,000,000 | ||
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| AVIS BUDGET GROUP, INC. | AVIS BUDGET GROUP, INC. | $240,000 |
| TUNGSTEN MINING NL | SQUIRE PATTON BOGGS | $120,000 |
| NISSAN NORTH AMERICA, INC. | SQUIRE PATTON BOGGS | $80,000 |
| LEARN ALLIANCE (INFORMAL COALITION) | CAPITOL TAX PARTNERS, LLP | $40,000 |
| FRAYM | CASSIDY & ASSOCIATES, INC. | $40,000 |
| VIEGA LLC | SQUIRE PATTON BOGGS | $30,000 |
| GLOBAL TECHNICAL SYSTEMS | GLOBAL TECHNICAL SYSTEMS | $30,000 |
| ML STRATEGIES, LLC (ON BEHALF OF DAIKIN U.S. CORPORATION) | PLURUS STRATEGIES, LLC | $30,000 |
| LIBERTY MUTUAL GROUP INC. | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $30,000 |
| SONOVA USA. INC. | AMERICAN CAPITOL GROUP | $30,000 |
| THE MCKEON GROUP INC. (ON BEHALF OF D-WAVE GOVERNMENT INC.) | PLURUS STRATEGIES, LLC | $30,000 |
| ML STRATEGIES, LLC (ON BEHALF OF PRICESMART, INC.) | PLURUS STRATEGIES, LLC | $20,000 |
| NLMK PENNSYLVANIA | SQUIRE PATTON BOGGS | $10,000 |
| THE CORMAC GROUP, ON BEHALF OF TENDO | AMERICAN CAPITOL GROUP | undisclosed |
| AMERICAN PETROLEUM INSTITUTE (API) | KELLER AND HECKMAN, LLP | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Kevin Mullin, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
